Of note, in the SURMOUNT-1 phase III trial performed in adults with obesity, once-weekly tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), demonstrated substantial reductions in body weight of up to 22.5%, with greater improvements than placebo in cardiometabolic risk factors, including waist circumference, systolic and diastolic blood pressure, and fasting insulin, lipid, and aspartate aminotransferase levels (62). Here, GIP is linked to Obesity.